Enhancement of anti-tumor CD8 immunity by IgG1-mediated targeting of Fc receptors

mAbs

Volumn 6, Issue 1, 2014, Pages 108-118

  Furlan, Scott N ^a   Mandraju, Rajakumar ^b   Brewer, Travis ^b   Roybal, Kole ^b   Troutman, Ty Dale ^b   Hu, Wei ^b   Palm, Noah W ^c   Unni, Arun ^d   Pasare, Chandrashekhar ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

Cancer vaccine; CD8 T cell priming; Cross presentation; Dendritic cells; Fc receptors; IgG1; MHC Class I

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN 1 FC FRAGMENT RECEPTOR VACCINE; TUMOR VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CD8+ T LYMPHOCYTE; CELL SURFACE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; DRUG TARGETING; IMMUNE RESPONSE; IMMUNOPHARMACOLOGY; IN VIVO STUDY; LYMPHOMA CELL LINE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR CELL; TUMOR IMMUNITY;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; LYMPHOMA; MICE; NEOPLASM PROTEINS; RECEPTORS, FC;

EID: 84892605023     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.27052     Document Type: Article

References (54)

1. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011; 29:3085-96; PMID:21383288; http://dx.doi. org/10.1200/JCO.2010.33.2312
2. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299-308; PMID:18354418; http://dx.doi. org/10.1038/nrc2355 (Pubitemid 351430867)
3. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:26577; PMID:22437871; http://dx.doi.org/10.1038/ nrc3258
4. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi. org/10.1038/nrc3239
5. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010; 327:291-5; PMID:20075244; http://dx.doi. org/10.1126/science.1183021
6. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al.; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:41122; PMID:20818862; http://dx.doi.org/10.1056/ NEJMoa1001294
7. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol 2012; 12:557-69; PMID:22790179; http://dx.doi. org/10.1038/nri3254
8. Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol 2011; 29:4828-36; PMID:22042955; http://dx.doi. org/10.1200/JCO.2011. 38.0899
9. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003; 15:138-47; PMID:12633662; http://dx.doi.org/10.1016/S0952-7915(03)00015-3 (Pubitemid 36287518)
10. Bousso P, Robey E. Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. Nat Immunol 2003; 4:579-85; PMID:12730692; http:// dx.doi.org/10.1038/ni928 (Pubitemid 36701342)
11. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989; 54:1-13; PMID:2700931; http://dx.doi.org/10.1101/SQB.1989.054.01.003
12. Flinsenberg TW, Compeer EB, Koning D, Klein M, Amelung FJ, van Baarle D, Boelens JJ, Boes M. FCY receptor antigen targeting potentiates cross-presentation by human blood and lymphoid tissue BDCA-3+ dendritic cells. Blood 2012; 120:516372; PMID:23093620; http://dx.doi.org/10.1182/ blood-2012-06-434498
13. Cruz LJ, Rueda F, Cordobilla B, Simon L, Hosta L, Albericio F, Domingo JC. Targeting nanosystems to human DCs via Fc receptor as an effective strategy to deliver antigen for immunotherapy. Mol Pharm 2011; 8:104-16; PMID:21121669; http://dx.doi. org/10.1021/mp100178k
14. Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 2012; 30:122; PMID:22136168; http://dx.doi.org/10.1146/ annurev-immunol-100311-102839
15. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8:34-47; PMID:18064051; http://dx.doi. org/10.1038/nri2206
16. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19:275-90; PMID:11244038; http:// dx.doi.org/10.1146/annurev.immunol.19.1.275 (Pubitemid 32368037)
17. Nimmerjahn F, Ravetch JV. Antibodies, Fc receptors and cancer. Curr Opin Immunol 2007; 19:23945; PMID:17291742; http://dx.doi.org/10.1016/j. coi.2007.01.005
18. Desai DD, Harbers SO, Flores M, Colonna L, Downie MP, Bergtold A, Jung S, Clynes R. Fc gamma receptor IIB on dendritic cells enforces peripheral tolerance by inhibiting effector T cell responses. J Immunol 2007; 178:6217-26; PMID:17475849 (Pubitemid 46717404)
19. Boross P, Leusen JH. Mechanisms of action of CD20 antibodies. Am J Cancer Res 2012; 2:676-90; PMID:23226614
20. Pokrass MJ, Liu MF, Lindorfer MA, Taylor RP. Activation of complement by monoclonal antibodies that target cell-associated (-microglobulin: implications for cancer immunotherapy. Mol Immunol 2013; 56:549-60; PMID:23911412; http://dx.doi.org/10.1016/j.molimm.2013.05.242
21. Boross P, Lohse S, Nederend M, Jansen JH, van Tetering G, Dechant M, Peipp M, Royle L, Liew LP, Boon L, et al. IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol Med 2013; 5:121326; PMID:23918228; http://dx.doi.org/10.1002/ emmm.201201929
22. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12:278-87; PMID:22437872; http://dx.doi.org/10.1038/ nrc3236
23. Signorino E, Brusa D, Granata R, Malavasi F, Ferrone S, Matera L. Contribution of dendritic cells' FcgammaRI and FcgammaRIII to cross-presentation of tumor cells opsonized with the anti-MHC class I monoclonal antibodies. Cancer Biol Ther 2007; 6:1932-7; PMID:18087220; http://dx.doi. org/10.4161/cbt.6.12.4973 (Pubitemid 351590406)
24. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 2002; 195:12533; PMID:11781371; http://dx.doi.org/10.1084/ jem.20011097
25. Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet 2009; 373:1033-40; PMID:19304016; http://dx.doi. org/10.1016/S0140-6736(09)60251-8
26. Rafiq K, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 2002; 110:71-9; PMID:12093890 (Pubitemid 34743467)
27. Harbers SO, Crocker A, Catalano G, D'Agati V, Jung S, Desai DD, Clynes R. Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance. J Clin Invest 2007; 117:1361-9; PMID:17446931; http://dx.doi.org/10.1172/JCI29470 (Pubitemid 46718424)
28. Getahun A, Dahlstrom J, Wernersson S, Heyman B. IgG2a-mediated enhancement of antibody and T cell responses and its relation to inhibitory and activating Fc gamma receptors. J Immunol 2004; 172:5269-76; PMID:15100265 (Pubitemid 38542024)
29. Regnault A, Lankar D, Lacabanne V, Rodriguez A, Thery C, Rescigno M, Saito T, Verbeek S, Bonnerot C, Ricciardi-Castagnoli P, et al. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 1999; 189:37180; PMID:9892619; http://dx.doi.org/10.1084/ jem.189.2.371
30. Amigorena S. Fc gamma receptors and cross-presentation in dendritic cells. J Exp Med 2002; 195:F1-3; PMID:11781374; http://dx.doi. org/10.1084/jem.20011925 (Pubitemid 34074490)
31. den Haan JM, Bevan MJ. Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(-) dendritic cells in vivo. J Exp Med 2002; 196:817-27; PMID:12235214; http://dx.doi.org/10.1084/jem. 20020295
32. Stabila PF, Wong SC, Kaplan FA, Tao W. Cell surface expression of a human IgG Fc chimera activates macrophages through Fc receptors. Nat Biotechnol 1998; 16:1357-60; PMID:9853619; http://dx.doi. org/10.1038/4339 (Pubitemid 28547448)
33. Takashima Y, Tsukamoto M, Ota H, Matsumoto Y, Hayashi Y, Otsuka H. Immunization with pseudorabies virus harboring Fc domain of IgG makes a contribution to protection of mice from lethal challenge. Vaccine 2005; 23:3775-82; PMID:15893614; http://dx.doi.org/10.1016/j. vaccine.2005.02.031 (Pubitemid 40704740)
34. Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988; 54:77785; PMID:3261634; http://dx.doi.org/10.1016/ S0092-8674(88)91043-4
35. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995; 1:1297-302; PMID:7489412; http:// dx.doi.org/10.1038/nm1295-1297
36. Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res 2000; 60:3239-46; PMID:10866317 (Pubitemid 30407923)
37. Clarke SR, Barnden M, Kurts C, Carbone FR, Miller JF, Heath WR. Characterization of the ovalbumin-specific TCR transgenic line OT-I: MHC elements for positive and negative selection. Immunol Cell Biol 2000; 78:110-7; PMID:10762410; http://dx.doi. org/10.1046/j.1440-1711.2000.00889.x (Pubitemid 30220105)
38. Barnden MJ, Allison J, Heath WR, Carbone FR. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol 1998; 76:34-40; PMID:9553774; http://dx.doi. org/10.1046/j.1440-1711.1998.00709.x (Pubitemid 28194695)
39. Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C, Salazar AM, Colonna M, Steinman RM. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 2009; 206:1589-602; PMID:19564349; http:// dx.doi.org/10.1084/jem.20090247
40. Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 2010; 28:43909; PMID:20697078; http://dx.doi.org/10. 1200/ JCO.2009.27.6360
41. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 2002; 195:12533; PMID:11781371; http://dx.doi.org/10.1084/ jem.20011097
42. Harbers SO, Crocker A, Catalano G, D'Agati V, Jung S, Desai DD, Clynes R. Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance. J Clin Invest 2007; 117:1361-9; PMID:17446931; http://dx.doi.org/10.1172/JCI29470 (Pubitemid 46718424)
43. Regnault A, Lankar D, Lacabanne V, Rodriguez A, Thery C, Rescigno M, Saito T, Verbeek S, Bonnerot C, Ricciardi-Castagnoli P, et al. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 1999; 189:37180; PMID:9892619; http://dx.doi.org/10.1084/ jem.189.2.371
44. Harshyne LA, Watkins SC, Gambotto A, Barratt-Boyes SM. Dendritic cells acquire antigens from live cells for cross-presentation to CTL. J Immunol 2001; 166:3717-23; PMID:11238612 (Pubitemid 32224894)
45. Nierkens S, Tel J, Janssen E, Adema GJ. Antigen cross-presentation by dendritic cell subsets: one general or all sergeants? Trends Immunol 2013; 34:361-70; PMID:23540650; http://dx.doi.org/10.1016/j. it.2013.02.007
46. Asano K, Nabeyama A, Miyake Y, Qiu CH, Kurita A, Tomura M, Kanagawa O, Fujii S, Tanaka M. CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. Immunity 2011; 34:85-95; PMID:21194983; http:// dx.doi.org/10.1016/j.immuni.2010.12.011
47. Tseng D, Volkmer JP, Willingham SB, Contreras-Trujillo H, Fathman JW, Fernhoff NB, Seita J, Inlay MA, Weiskopf K, Miyanishi M, et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci U S A 2013; 110:111038; PMID:23690610; http://dx.doi.org/10.1073/ pnas.1305569110
48. Pardigon N, Bercovici N, Calbo S, Santos-Lima EC, Liblau R, Kourilsky P, Abastado JP. Role of co-stimulation in CD8+ T cell activation. Int Immunol 1998; 10:619-30; PMID:9645610; http:// dx.doi.org/10.1093/intimm/10.5.619 (Pubitemid 28221463)
49. Shahinian A, Pfeffer K, Lee KP, Kiindig TM, Kishihara K, Wakeham A, Kawai K, Ohashi PS, Thompson CB, Mak TW. Differential T cell costimulatory requirements in CD28-deficient mice. Science 1993; 261:609-12; PMID:7688139; http:// dx.doi.org/10.1126/science.7688139 (Pubitemid 23278372)
50. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003; 421:8526; PMID:12594515; http://dx.doi.org/10.1038/ nature01441
51. Riddle DS, Sanz L, Chong H, Thompson J, Vile RG. Tumor cell surface display of immunoglobulin heavy chain Fc by gene transfer as a means to mimic antibody therapy. Hum Gene Ther 2005; 16:83044; PMID:16000065; http://dx.doi.org/10.1089/ hum.2005.16.830
52. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003; 299:1033-6; PMID:12532024; http://dx.doi. org/10.1126/science.1078231 (Pubitemid 36222922)
53. Pasare C, Medzhitov R. Toll-dependent control mechanisms of CD4 T cell activation. Immunity 2004; 21:733-41; PMID:15539158; http://dx.doi. org/10.1016/j.immuni.2004.10.006 (Pubitemid 39487894)
54. Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nude mouse. J Surg Oncol 1986; 31:229-34; PMID:3724177; http://dx.doi. org/10.1002/jso.2930310402 (Pubitemid 16104025)